A groundbreaking new study in 'Nature,' from a Novo Nordisk-funded research lab, boasts a drug that works better on mice than ...
Staff in the Senate Health, Education, Labor, and Pensions (HELP) committee, which Sanders chairs, estimate that widespread ...
The US Senator took another swipe at the US prices of Novo Nordisk’s blockbuster GLP-1 receptor agonist drugs Ozempic and ...
Sen. Bernie Sanders released a report on Wednesday detailing how popular weight loss drugs could bankrupt America's health ...
Study participants randomly received either semaglutide or a placebo for 52 weeks. Participants were divided into those not receiving diuretics, a subset receiving non-loop diuretics only, and a ...
Weight loss drugs have the potential to bankrupt the U.S. healthcare system, according to a May 15 report from Sen. Bernie Sanders's office. Mr. Sanders chairs the Senate Committee on Health, ...
“Both the WC-to-height ratio and the waist-to-hip ratio have been recognized as predictors of cardiovascular disease (CVD) ...
Separately, even though the price of anti-obesity drugs is high, Medicare could save about $500 million a year by covering them. The Hill: Wegovy Could Bankrupt US Health System, Sanders Says In New ...
After recently placing a spotlight on Novo Nordisk’s "outrageous" U.S. | A new Senate HELP Committee report says GLP-1 drugs ...
If Novo Nordisk dropped the price of Wegovy in the U.S down to the price in Denmark, the U.S. health care system could pay for new weight loss drugs for 100% of adults with obesity for less than the ...
A closer look at the numbers helps to explain the shift in political discourse from coverage to affordability. Also in the news: pressure to reduce drug prices, removing insurance perks for seniors, ...
About 1 in 8 adults in the United States has used a GLP-1 drug like Ozempic or Mounjaro at some point in their life.